Ten-year results following treatment of intrabony defects with an enamel matrix protein derivative combined with either a natural bone mineral or a β-tricalcium phosphate

Döri, Ferenc; Arweiler, Nicole B.; Szántó, Erika; Ágics, Anikó; Gera, István; Sculean, Anton (2013). Ten-year results following treatment of intrabony defects with an enamel matrix protein derivative combined with either a natural bone mineral or a β-tricalcium phosphate. Journal of periodontology, 84(6), pp. 749-757. American Academy of Periodontology 10.1902/jop.2012.120238

[img] Text
JPerio.pdf - Published Version
Restricted to registered users only
Available under License Publisher holds Copyright.

Download (527kB) | Request a copy

BACKGROUND The purpose of the present study is to evaluate the 10-year results following treatment of intrabony defects treated with an enamel matrix protein derivative (EMD) combined with either a natural bone mineral (NBM) or β-tricalcium phosphate (β-TCP). METHODS Twenty-two patients with advanced chronic periodontitis and displaying one deep intrabony defect were randomly treated with a combination of either EMD + NBM or EMD + β-TCP. Clinical evaluations were performed at baseline and at 1 and 10 years. The following parameters were evaluated: plaque index, bleeding on probing, probing depth, gingival recession, and clinical attachment level (CAL). The primary outcome variable was CAL. RESULTS The defects treated with EMD + NBM demonstrated a mean CAL change from 8.9 ± 1.5 mm to 5.3 ± 0.9 mm (P <0.001) and to 5.8 ± 1.1 mm (P <0.001) at 1 and 10 years, respectively. The sites treated with EMD + β-TCP showed a mean CAL change from 9.1 ± 1.6 mm to 5.4 ± 1.1 mm (P <0.001) at 1 year and 6.1 ± 1.4 mm (P <0.001) at 10 years. At 10 years two defects in the EMD + NBM group had lost 2 mm, whereas two other defects had lost 1 mm of the CAL gained at 1 year. In the EMD + β-TCP group three defects had lost 2 mm, whereas two other defects had lost 1 mm of the CAL gained at 1 year. Compared with baseline, at 10 years, a CAL gain of ≥3 mm was measured in 64% (i.e., seven of 11) of the defects in the EMD + NBM group and in 82% (i.e., nine of 11) of the defects in the EMD + β-TCP group. No statistically significant differences were found between the 1- and 10-year values in either of the two groups. Between the treatment groups, no statistically significant differences in any of the investigated parameters were observed at 1 and 10 years. CONCLUSION Within their limitations, the present findings indicate that the clinical improvements obtained with regenerative surgery using EMD + NBM or EMD + β-TCP can be maintained over a period of 10 years.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > School of Dental Medicine > Department of Periodontology

UniBE Contributor:

Sculean, Anton

Subjects:

600 Technology > 610 Medicine & health

ISSN:

0022-3492

Publisher:

American Academy of Periodontology

Language:

English

Submitter:

Eveline Carmen Schuler

Date Deposited:

25 Feb 2014 10:31

Last Modified:

25 Jan 2017 12:15

Publisher DOI:

10.1902/jop.2012.120238

PubMed ID:

22873657

Uncontrolled Keywords:

Bone grafting, enamel matrix proteins, periodontitis, randomized controlled trial, regenerative medicine

BORIS DOI:

10.7892/boris.40638

URI:

https://boris.unibe.ch/id/eprint/40638

Actions (login required)

Edit item Edit item
Provide Feedback